OCIAD1 Antibodies

Santa Cruz Biotechnology supplies a comprehensive collection of OCIAD1 monoclonal antibodies for research focused on understanding OCIAD1's role in various biological processes. Multiple detection methods are supported, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). OCIAD1, or Ovarian Cancer Immunoreactive Antigen Domain 1, plays important roles in cellular processes such as apoptosis and cell proliferation. OCIAD1 expression patterns show significant correlation with ovarian cancer development and progression. Understanding OCIAD1's molecular mechanisms and interactions provides valuable insights for cancer biology research. Investigating OCIAD1 function helps identify new biomarkers for improved diagnosis and treatment approaches. Current research explores OCIAD1's potential as a therapeutic target in cancer treatment strategies. Ongoing studies continue to reveal new aspects of OCIAD1's biological significance and clinical applications. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of OCIAD1 and its implications in cancer biology.